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Background: Fluticasone furoate (FF)/vilanterol (VI) is a once-daily inhaled corticosteroid (ICS)/long-acting beta2
agonist (LABA) combination. FF/VI, 92/22mcg and 184/22mcg, are approved in Europe as maintenance therapy in
persistent asthma. We report data from mixed treatment comparisons (MTC) of once-daily FF/VI against established
twice-daily ICS/LABA combination therapies on clinical efficacy outcomes.
Methods: Data from 31 parallel-group randomised controlled trials (RCTs) of ICS/LABA, of ≥8 weeks’ duration in
patients aged ≥12 years with asthma, identified by systematic review, were analysed using covariate-adjusted
Bayesian hierarchical models for four efficacy outcomes (primary analysis). Lung function, assessed by change from
baseline morning peak expiratory flow (PEF) (n = 18 studies) and forced expiratory volume in 1 s (FEV1) (n = 28), was
the outcome of primary interest. Secondary objectives were assessment of relative efficacy in terms of exacerbation
rates (n = 6) and health status (n = 7). Overall, 24 different treatment arms were included in the MTC; we report findings
comparing FF/VI (92/22mcg and 184/22mcg) with fluticasone propionate/salmeterol (FP/SAL) (250/50mcg and 500/
50mcg) and budesonide/formoterol (BUD/FORM) (320/9mcg and 640/18mcg).
Results: For PEF (margin = 12 l/min), FF/VI 92/22mcg demonstrated ≥94 % probability and FF/VI 184/22mcg >99 %
probability of non-inferiority to corresponding doses of both FP/SAL and BUD/FORM. For FEV1 (margin = 100 ml), FF/VI
demonstrated ≥98 % (92/22mcg) and >99 % (184/22mcg) probability of non-inferiority to both FP/SAL and BUD/FORM.
Findings for exacerbations were inconclusive due to lack of data: FF/VI 92/22mcg demonstrated 74 % and 82 %
probability of non-inferiority (margin = 10 %) to FP/SAL 250/50mcg and BUD/FORM 320/9mcg, respectively. For
Asthma Quality of Life Questionnaire (AQLQ) score, FF/VI 92/22mcg demonstrated >99 % and 90 % probability of
non-inferiority (margin = 0.25) to FP/SAL 250/50mcg and BUD/FORM 320/9mcg. Data were unavailable to assess
non-inferiority of FF/VI 184/22mcg on exacerbations or AQLQ.
Conclusions: Both strengths of once-daily FF/VI in asthma were comparable with corresponding doses of twice-daily
FP/SAL and BUD/FORM in terms of lung function in this MTC analysis. FF/VI 92/22mcg was comparable with FP/SAL
and BUD/FORM on AQLQ, but exacerbation results were inconclusive. Model limitations include disconnected treatment
networks and variability across studies. Our data support previous RCT findings suggesting that the efficacy of once-daily
FF/VI in improving lung function and health status in asthma is comparable with twice-daily ICS/LABAs.
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Fluticasone furoate (FF)/vilanterol (VI) is an inhaled
corticosteroid (ICS)/long-acting beta2 agonist (LABA)
combination approved in 2013 in Europe and Japan for
the treatment of asthma. Both FF and VI have been shown
to display 24-h activity in pre-clinical studies [1, 2], and a
single daily dose of FF/VI has been shown to produce
long-lasting improvement in lung function in patients
with asthma [3]. Once-daily FF/VI, at strengths of 92/22
mcg and 184/22 mcg, has been shown to be well tolerated,
with no safety profile findings of significant clinical
concern, in a 12-month randomised controlled trial in pa-
tients aged ≥12 years with persistent moderate-severe
asthma [4]. FF/VI therefore represents the first once-daily
combination therapy approved for use in asthma.
The efficacy of FF/VI in asthma has been assessed in sev-
eral randomised controlled trials (RCTs). The effects of
once daily FF/VI 92/22 mcg (delivered dose; nominal dose
is 100/25 mcg) on lung function and patient-reported
health status have been compared in RCTs with FF 100
mcg [3, 5], and once-daily FF/VI 184/22 mcg (delivered
dose; nominal dose is 200/25 mcg) has been compared
with once-daily FF 200 mcg alone and twice-daily FP 500
mcg [6]. Once-daily FF/VI 92/22 mcg has also been com-
pared in a head-to-head study with twice daily FP/SAL
250/50 mcg [7]. One study of the efficacy in reducing ex-
acerbation rate of FF/VI 92/22 mcg compared with FF
monotherapy has been reported [5]. However, the efficacy
of once-daily FF/VI has not, as of the time of writing, been
directly compared in any RCT with that of twice-daily
combination therapies other than FP/SAL; some of which,
such as budesonide (BUD)/formoterol (FORM), are widely
used in the clinical management of asthma.
We sought to evaluate the relative therapeutic efficacy of
FF/VI in asthma by making maximal use of the body of
RCT data available. Indirect treatment comparisons, such
as the mixed treatment comparison (MTC), provide a
means of estimating the relative efficacy of treatments that
have not been directly compared in an RCT, and broaden
the evidence base for those treatments which have already
been compared in head-to-head studies. We applied the
MTC approach to compare the treatment efficacy of once-
daily FF/VI 92/22 mcg and 184/22 mcg with corresponding
strengths of alternative licensed twice-daily ICS/LABA
combination therapies on four clinically-relevant out-
comes. For each outcome, we combined data from separate
RCTs, all of which were identified through a systematic
literature review and involved at least one ICS/LABA com-
parator, in Bayesian, hierarchical models. These models
were used to make inferences about relative treatment
efficacy within the combined ICS/LABA therapy class and
derive probabilities of non-inferiority and superiority for
four clinically relevant outcomes: peak expiratory flow
(PEF), forced expiratory volume in 1 s (FEV1), moderate/severe exacerbation rate, and asthma quality of life ques-
tionnaire (AQLQ/AQLQ(S) Total score). The primary
focus of the analyses was on the non-inferiority results.Methods
Systematic literature review
A systematic literature review was conducted to iden-
tify Phase III and Phase IV parallel-group RCTs of any
ICS/LABA maintenance therapies vs any drug, placebo
or standard of care comparator, of >8 weeks duration,
in patients aged ≥12 years with asthma who were receiving
ICS or ICS/LABA maintenance therapy at randomisation.
Studies that required patients to be uncontrolled/symp-
tomatic at baseline were eligible for inclusion in the MTC.
Studies that included patients who were controlled/asymp-
tomatic at baseline, predominantly recruited stable patients
(explicitly defined or suggested by baseline averages of key
parameters) or required patients to have a history of stable
asthma, or did not report control or symptom status at
randomisation were excluded. Additionally, studies
containing ≥1 flexible dosing or dose-ranging arm were
excluded.
A secondary MTC analysis, the ‘ICS-only subset ana-
lysis’, was conducted including only the subset of studies
requiring patients to be treated with ICS only at base-
line, i.e. LABA use was not permitted at randomisation.
This approach identified studies in patient populations
likely to be eligible for treatment with FF/VI in accord-
ance with its European licence.
FF/VI trials were identified internally, and additional
studies were identified through the systematic searching
of clinical publication databases and clinical trial regis-
ters. Additionally, references in retrieved articles and
relevant systematic reviews were checked for further
studies that might fulfil the inclusion criteria. No date
limits were applied to the searches.Outcome assessment
The outcomes assessed were change from baseline in
lung function outcomes: PEF and FEV1, annual rate of
moderate/severe exacerbations, and change from base-
line in AQLQ health status questionnaire Total score.
Moderate/severe exacerbations were defined according
to the American Thoracic Society/European Respira-
tory Society Task Force recommendation [8] as deterio-
rations of asthma requiring the use of systemic/oral
corticosteroids for ≥3 days, or emergency department
visit or in-patient hospitalisation due to asthma requir-
ing the use of systemic corticosteroids.
The outcome of primary interest, effect of treatment on
lung function, was studied through the assessment of two
measures of airflow limitation: PEF and FEV1. These mea-
sures are typically well correlated with each other [9].
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systematic literature review were included in the MTC if
they reported the precise outcome or sufficient calculable
information in a suitable format. For PEF, to minimise
study-to-study variability, studies were included only if
they reported mean changes from baseline averaged over
the entire duration of the trial. For exacerbations, studies
were included in the MTC if they reported either the rate
or number of moderate/severe exacerbations as defined
above. Studies that allowed changes in symptoms, rescue
use or lung function to be classed as exacerbations were
excluded, as were those that withdrew patients once they
experienced an exacerbation. With a single exception of
arms consisting of steroid-naive patients in one study [10],
all treatment arms from included studies were incorpo-
rated into the MTC.
The selection of margins that were used in the probabil-
istic assessment of non-inferiority for each outcome was in-
formed by the margins specified in the design of previously
reported comparative studies. For PEF, non-inferiority mar-
gins of 12 l/min and 15 l/min were selected on the basis of
published guidelines [11]. For exacerbations, event rate
ratios of 0.1 and 0.2 were used as non-inferiority margins
on the basis of previous comparative studies [12]. For FEV1
(75 ml, 100 ml and 125 ml) and AQLQ (0.25 and 0.5), the
non-inferiority margins used were based upon the accepted
minimal clinically important difference (MCID) [13, 14].
Modelling strategy
The MTC modelling approach used in this analysis
employed a Bayesian, hierarchical methodology to esti-
mate relative treatment effects, accounting for variability
across studies by parameterising the study effect. The
Bayesian approach [15–17] was decided upon prior to
the commencement of the systematic literature review.
This methodology enables the comparison of the effects
of treatments that have never been directly compared in
the same clinical trial, and is compatible with inference
from weak or disconnected treatment networks [18].
For each outcome, a hierarchical random effects model
was constructed in which the effect of each included study
α was modelled with a distribution αS ~N(μ, τ
2). The two
parameters μ and τ were then modelled with second-level
hyperpriors and a posterior distribution created. Treat-
ment effects, with independent prior distributions, were
modelled separately as a single parameter, thus enabling
probabilistic treatment comparisons to be derived to-
gether with credible intervals (CrI) for the differences in
effect sizes.
For PEF, FEV1 and AQLQ Total score, the continuous
change from baseline outcomes was modelled using Nor-
mal distributions. The mean treatment effect was modelled
with the following distribution: Y~N(αs + θt + βZ , σ
2), with
the non-informative prior σα
2 ~ Inverse −Gamma(0.001,0.001) and hyperpriors μs~N(0, 10
2) and τ2 ~ Inverse −
Gamma(0.001, 0.001). The parameters α and θ represent,
respectively, the studies included in the analysis, and the
treatment regimen effects. The Z’s represent the covariates
and the β’s represent the coefficients (i.e. the covariate
effects). Each treatment effect is modelled independently
with the flat prior distribution N(0, 1002).
For exacerbations, the yearly rate was modelled using a
Poisson distribution, as follows: Exac ~ Poisson(Rate*per-
son-years), in which log(Rate) = αs + θt + βZ. Priors and
model parameters for the study and treatment effects were
defined as for the other three outcomes; treatment regi-
men effects are represented by θ. Each treatment effect is
modelled independently with the flat prior distribution
N(0, 52). The placebo arms are designated as t = 0 and are
used as the baseline treatment. The original analysis plan
was to use a standard deviation of 100 for the treatment
effects. This represents a very flat, non-informative prior
distribution. However, the outcome of one trial arm with
0 events makes for a non-identifiable outcome which,
combined with the very flat prior, creates numerical stabil-
ity issues. Therefore, a vague prior of 5 is selected for the
treatment arms, creating stable estimates and more inter-
pretable model results.
Rate was defined as number of exacerbations divided
by person-years of follow-up. Person-years of follow-up
were computed directly if both the rate and number of
events were available or were estimated if neither were
available. When estimated, subjects not lost to follow-up
were assumed to have had complete (100 %) follow-up.
Subjects lost to follow-up were assumed to have 50 % of
the possible follow-up. When the number of events was
not reported, the rate and estimated person-years of
follow-up were used to estimate the number of moder-
ate/severe exacerbation events.
The following covariates were included in the full covari-
ate model for all outcomes: study duration; age at baseline;
gender; baseline mean FEV1. The continuous covariates–
age, gender and baseline mean FEV1–were normalised.
Specifically, age was normalised by subtracting 40 years of
age; the resulting covariate is “Age–40”. Gender is repre-
sented as the percentage of males in a treatment arm.
Gender was normalised by subtracting 40 % from the
treatment arm population of males, thus the covariate is
“%Male–40”. Baseline FEV1 is normalised by subtracting
2.4; the resulting covariate is “FEV1–2.4”. The single cat-
egorical variable, length of study, had a designated refer-
ence group of studies 40–60 weeks in length, i.e. those
that were approximately 1 year in length.
In treatment arms with missing covariate information,
mean values were imputed across all treatment arms.
Attempts were made to fit full covariate models for all
outcomes of interest, but this could not be achieved for
exacerbations as data limitations meant the full covariate
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reported only for the time-covariate model, in which
only study duration was modelled as a covariate. For the
other three outcomes, findings from the full covariate
model are reported.
Model fit was assessed by evaluating the difference be-
tween the model-estimated values and observed values,
divided by the estimated standard deviation (SD).
All analyses were carried out using standard Markov
Chain Monte Carlo methodology, utilising adaptive
Metropolis-Hastings steps where applicable [19], and were
performed using custom software written in ANSI-
standard Fortran (Berry Consultants LLC, Austin, TX).
The software used was independently validated with du-
plicate code written in R (R Development Core Team,
Vienna, Austria).
Sensitivity analysis
Sensitivity analyses, in which studies that were excluded
under the primary analysis criteria were added to the
model, were performed for the PEF and exacerbation
rates outcomes of interest, using the same modelling
approach as in the main analyses. For the outcome of
change from baseline PEF, the sensitivity analysis in-
cluded an additional nine studies that were excluded
from the main analysis because they did not report
change in PEF from baseline to study end. The PEF
sensitivity analysis network was thus constructed using
data from 27 studies. For exacerbations, one of the sen-
sitivity analyses included an additional six studies that
were excluded from the main analysis because they with-
drew patients and discontinued their follow-up after
they reported an exacerbation, for a sensitivity analysis
network consisting of data from 12 studies.
In separate sensitivity analyses performed for the exacer-
bation rate network, the data for the original six studies
were re-analysed using alternate versions of the person-
years calculation for those cases where person-years were
estimated. Two such analyses were conducted, using an
assumed follow-up time for patients lost to follow-up of
25 % or 75 %, respectively, rather than 50 % as in the main
analysis.
Assessment of alternative modelling approaches
Two post-hoc validation analyses were performed on the
same dataset using alternative methods in order to evaluate
the extent to which outcomes were susceptible to the pri-
mary model chosen: a frequentist analysis using a random
effects model with fixed study and treatment effects,
reporting p-values was performed on all four outcomes of
interest using R (lme4 package); and a pairwise contrast
analysis using a Bayesian random effects model was per-
formed on the FEV1 data only using geMTC software [20]
running WinBUGS [21]. As geMTC did not enableautomated analyses of rates with Poisson distributions,
exacerbation rates were approximated as continuous vari-
ables, comparing rate differences rather than rate ratios. In
the validation analyses, point estimates with confidence or
credible intervals were calculated, with the frequentist
analyses also reporting p-values.
Results
Study selection
Thirty-six unique studies were considered for inclusion
in the MTC. A total of 31 parallel-group trials, with 23
different drug treatments plus placebo, were included in
at least one of the four primary analyses (Fig. 1). For the
primary analysis populations, eighteen studies were in-
cluded in the analysis of change from baseline PEF; 28
for FEV1; seven for AQLQ; and six for exacerbation rates
(Additional file 1: e-table 1).
For the ICS-only subset analysis, the study sets were
the same for PEF and exacerbations, and slightly smaller
for FEV1 and AQLQ (26 and six studies, respectively).
The studies and treatment arms included in the MTC
are summarised in Table 1. Reasons for exclusion of
studies from each analysis are outlined in the Additional
file 1. The networks of studies included for each outcome
of interest are shown in Fig. 1 and Additional file 1:
Supplementary Figure 1.
Primary analysis
Change from baseline PEF
Placebo treatment was associated with a slight mean
(SD) decrease from baseline of –1.7 (8.9) l/min. All ICS/
LABA combination therapies included in the model
were associated with mean (SD) improvements from
baseline PEF ranging from 19.65 (8.55) l/min with BUD/
FORM 100/6 mcg to 49.94 (7.63) l/min with FF/VI 184/
22 mcg (Fig. 2 and Additional file 1: e-table 2).
Based on a non-inferiority margin of 12 l/min, FF/VI 92/
22 mcg demonstrated 97 % and 94 % probability of non-
inferiority to corresponding doses of twice-daily FP/SAL
250/50 mcg and BUD/FORM 320/9 mcg, respectively
(Table 2). On the same margin, FF/VI 184/22 mcg
demonstrated >99 % probability of non-inferiority to
corresponding doses of both FP/SAL 500/50 mcg and
BUD/FORM 640/18 mcg. Based on a non-inferiority
margin of 15 l/min, FF/VI 92/22 mcg demonstrated
99 % and 98 % probability of non-inferiority to corre-
sponding doses of twice-daily FP/SAL 250/50 mcg
and BUD/FORM 320/9 mcg, respectively. On the
same margin, FF/VI 184/22 mcg demonstrated >99 %
probability of non-inferiority to doses of both FP/SAL
500/50 mcg and BUD/FORM 640/18 mcg. Of the co-
variates analysed, only baseline FEV1 had a significant
effect on PEF, though the credible interval was wide
(Additional file 1: e-table 3).
Fig. 1 Networks of study treatments, by outcome of interest (primary analysis population). a change from baseline in morning PEF. b change from
baseline in FEV1. c annual rate of moderate/severe exacerbations. d AQLQ Total score. Note: All stated doses are mcg. Delivered doses are given for
FF/VI at the strengths licenced in Europe for the treatment of asthma, and for BUD/FORM. For all other treatments, nominal doses are given. Connecting
lines represent studies included in the model that directly compare the two treatments. The thickness of the line is proportional to the number of studies
comparing the two treatments. BDP = beclomethasone dipropionate, BID = twice daily, BUD = budesonide, F = formoterol, FEV1 = forced
expiratory volume in 1 s, FF = fluticasone furoate, FP = fluticasone propionate, HFA = hydrofluoroalkane, MMF = mometasone furoate,
QD = once daily; SAL = salmeterol, VI = vilanterol
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All ICS/LABA combination therapies were associated with
estimated improvements from baseline FEV1 of ≥147 ml,
whereas treatment with placebo was associated with a
mean (SD) decrease from baseline of 32 (58) ml. ICS/LABA
treatment was associated with mean (SD) improvements
from baseline, ranging from 147 (54) ml with FP/SAL 100/
50 mcg to 353 (67) ml with FF/VI 184/22 mcg (Fig. 2 and
Additional file 1: e-table 2).
Based on the most stringent of the three non-inferiority
margins assessed, 75 ml, FF/VI 92/22 mcg demonstrated
92 % and 91 % probability of non-inferiority to corre-
sponding doses of FP/SAL 250/50 mcg and BUD/FORM
320/9 mcg, respectively. On the same margin, FF/VI 184/
22 mcg demonstrated >99 % probability of non-inferiorityto corresponding doses of FP/SAL 500/50 mcg and
BUD/FORM 640/18 mcg (Table 2). On a slightly less
stringent margin of 100 ml, representing just under
half of the MCID [13], FF/VI 92/22 mcg demonstrated
99 % and 98 % probability, respectively, of non-
inferiority to corresponding doses of FP/SAL 250/50
mcg and BUD/FORM 320/9 mcg. On the same margin,
FF/VI 184/22 mcg demonstrated >99 % probability of
non-inferiority to corresponding doses of FP/SAL 500/
50 mcg and BUD/FORM 640/18 mcg. Based on the
non-inferiority margin of 125 ml, FF/VI 92/22 mcg and
184/22 mcg demonstrated >99 % probability of non-
inferiority to corresponding doses of FP/SAL 250/50
mcg and 500/50 mcg and BUD/FORM 320/9 mcg and
640/18 mcg, respectively. None of the model covariates
Table 1 Summary of studies and treatment arms included in
the primary mixed treatment comparison analysis
N (%) N (%)
Total studies 31 Total treatment arms 75
Endpoint reported Placebo 2 (3)
Change from baseline
in FEV1
28 (90) FF/VI 92/22 QD 3 (4)
Change from baseline
in PEF
18 (58) FF/VI 184/22 QD 1 (1)
Annual rate of exacerbations 6 (19) FF 100 QD 2 (3)
Change from baseline
in AQLQ
7 (23) FF 200 QD 1 (1)
Mean age reported 41.74 FP/SAL 100/50 BID 8 (11)
Mean percent male 40.51 FP/SAL 250/50 BID 11 (15)
Mean baseline FEV1 2.30 FP/SAL 500/50 BID 5 (7)
BUD/FORM 320/9 BID 12 (16)
BUD/FORM 640/18 BID 1 (1)
BUD/FORM 80/4.5 BID 2 (3)
BUD 360 BID 5 (7)
BUD 640 BID 2 (3)
BUD 360 BID 1 (1)




FORM 9 BID 1 (1)
FP 250 BID 3 (4)
FP 500 BID 4 (5)
FP 100 BID 1 (1)
FP 100 BID +
Montelukast 10 QD
3 (4)
FP/FORM 250/10 BID 1 (1)
MMF/F 200/10 BID 2 (3)
MMF/F 400/10 BID 1 (1)
Note: All stated doses are mcg. Delivered doses are given for FF/VI at the strengths
licenced in Europe for the treatment of asthma, and for BUD/FORM. For all other
treatments, nominal doses are given
AQLQ Asthma quality of life questionnaire, BDP Beclomethasone dipropionate,
BID Twice daily, BUD Budesonide, FORM Formoterol, FEV1 Forced expiratory
volume in one s, FF Fluticasone furoate, FP Fluticasone propionate, HFA
Hydrofluoroalkane, MMF Mometasone furoate, PEF Peak expiratory flow, QD
once daily, SAL Salmeterol, TIO Tiotropium, VI Vilanterol
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outcomes (Additional file 1: e-table 3).
Annual moderate/severe exacerbation rate
Relative to a benchmark rate of 1, based upon data from
the placebo arms of studies included in the model, ICS/
LABA combination therapies were associated with esti-
mated standardised event rate ratios of ≤0.203. The CrI
for the reduction in event rate ratio for all active treat-
ments excluded 1. The greatest reduction in event rate
ratio relative to placebo, 0.168 (95 % CrI: 0.088–0.236),was seen with twice-daily FP/SAL 250/50 mcg. The
estimated event rate ratio for once-daily FF/VI 92/22
mcg was 0.174 (95 % CrI: 0.070–0.443) (Fig. 2 and
Additional file 1: e-table 2).
Because of the disconnected network for the exacerba-
tion rate endpoint, the model included only one covariate,
study duration, as the addition of further covariates re-
sulted in the failure of the model to converge. Based on
non-inferiority margins representing a 10 % and 20 % re-
duction in event rate, FF/VI 92/22 mcg demonstrated
non-inferiority to FP/SAL 250/50 mcg with 74 % and
78 % probability, respectively. On the same margins, non-
inferiority to BUD/FORM 320/9 mcg was demonstrated
with 82 % and 86 % probability, respectively (Table 2).
However, credible intervals for the comparisons were very
wide owing to the weakness of the treatment network. No
data were available for the assessment of non-inferiority of
FF/VI 184/22 mcg to relevant comparators.
Change from baseline in AQLQ total score
All ICS/LABA combination therapies included in the
model were associated with estimated mean improve-
ments from baseline in AQLQ Total score. However,
because of the limited data available for the AQLQ
analysis, the CrI for all treatments were wide and did not
exclude zero for the comparison of any active treatment
with placebo (Fig. 3). Placebo treatment was associated
with an estimated mean (SD) improvement in score of
0.233 (0.485). The greatest mean (SD) improvement from
baseline for this outcome of interest, 0.854 (0.299), was
observed with FF/VI 184/22 mcg (Additional file 1: e-table
2). Non-inferiority findings could not be reported for the
higher strength of FF/VI; although the higher strength was
in the network, none of the comparable treatments of
interest were present.
Based on a non-inferiority margin of 0.25, representing
half of the MCID [14], FF/VI 92/22 mcg demonstrated
non-inferiority to corresponding doses of FP/SAL 250/50
mcg and BUD/FORM 320/9 mcg with >99 % and 90 %
probability, respectively (Table 2). For the non-inferiority
margin of 0.5, FF/VI 92/22 mcg demonstrated >99 % and
96 % probability of non-inferiority to corresponding doses
of FP/SAL 250/50 mcg and BUD/FORM 320/9 mcg,
respectively. None of the model covariates were found
to have a statistically significant effect on outcomes
(Additional file 1: e-table 3).
ICS-only subset analysis (Table 3 and Additional file 1:
e-table 4)
In the ICS-only subset analysis of the FEV1 data, the
exclusion of two studies permitting LABA use at base-
line resulted in a markedly greater observed decrease
from baseline FEV1 among patients receiving placebo.



















































































































































































92/22µg 184/22µg 250/50µg 500/50µg 360/9µg 640/18µg
FF/VI FP/SAL BUD/FORM
92/22µg 184/22µg 250/50µg 500/50µg 360/9µg 640/18µg
FF/VI FP/SAL BUD/FORM
92/22µg 184/22µg 250/50µg 500/50µg 360/9µg 640/18µg
FF/VI FP/SAL BUD/FORM
Fig. 2 Change from baseline versus placebo for selected treatments. For studies requiring patients to be treated with ICS or ICS/LABA at baseline;
full covariate analysis. a change from baseline in morning PEF. b change from baseline in FEV1. c annual rate of moderate/severe exacerbations.
d AQLQ Total score. AQLQ = Asthma Quality of Life Questionnaire, BUD = budesonide, FORM = formoterol, FEV1 = forced expiratory volume in 1 s,
FF = fluticasone furoate, FP = fluticasone propionate, PEF = peak expiratory flow, SAL = salmeterol, VI = vilanterol
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comparisons of FF/VI 92/22 mcg with FP/SAL 250/50
mcg and BUD/FORM 400/12 mcg, respectively. The
other probabilities of non-inferiority all remained higher
than 96 %. In the PEF and exacerbations analyses, no
studies were excluded in the ICS-only subset analysis for
annual moderate/severe exacerbation rate, so the out-
comes were unchanged from those of the main analysis.
The ICS-only subset analysis of the AQLQ data ex-
cluded one of the seven studies that were included in the
main analysis. As a consequence of non-convergence
owing to the weakness of the network of six studies, the
full covariate model could not be fit. A model including
only the study duration covariate was fit. The resulting
probability of non-inferiority of FF/VI 92/22 mcg to BUD/
FORM 320/9 mcg, on a non-inferiority margin of 0.25,
was 93 % and the probability of non-inferiority to FP/SAL
250/50 mcg of >99 % was unchanged. The mean (SD) im-
provement observed with placebo, 0.177 (0.414), was
lower than in the main analysis. The CrI for the treatment
difference vs placebo on the AQLQ outcome excluded
zero for both strengths of FF/VI and also for high-dose FPand FF monotherapy; for the remaining treatments in the
network, all other comparisons vs placebo included zero.
Sensitivity analysis (Additional file 1: e-table 5)
Sensitivity analyses, in which additional studies that did
not fulfil the primary analysis inclusion criteria were added
to the network, were conducted for the PEF and exacerba-
tions outcomes. For PEF, the addition of nine studies which
did not report change from baseline over the study dur-
ation up to study end to the 18 included in the primary
analysis resulted in reductions in the reported probabilities
of non-inferiority of FF/VI 92/22 mcg vs FP/SAL 250/50
mcg and BUD/FORM 320/9 mcg, whereas the results for
comparisons involving 184/22 mcg were similar to those
of the primary analysis. For exacerbations, the addition of
six studies that withdrew subjects and discontinued follow-
up after an exacerbation to the six included in the primary
analysis resulted in a narrowing of the credible intervals
for comparisons of FF/VI 92/22 mcg and increased prob-
abilities of non-inferiority vs FP/SAL 250/50 mcg and
BUD/FORM 320/9 mcg. It was also possible, using the
sensitivity analysis network, to report a probability of non-
Table 2 Posterior probability of non-inferiority for FF/VI versus other relevant ICS/LABA combination therapies*
A
Treatment (mcg) Comparator (mcg) Mean difference, l (95 % CrI) Probability of non-inferiority
Margin (l/min)
12 15
FF/VI 92/22 FP/SAL 250/50 2.832 (−12.867–18.531) 97 % 99 %
FF/VI 92/22 BUD/FORM 320/9 0.579 (−15.155–16.312) 94 % 98 %
FF/VI 184/22 FP/SAL 500/50 11.323 (0.289–22.357) >99 % >99 %
FF/VI 184/22 BUD/FORM 640/18 15.136 (−0.943–31.215) >99 % >99 %
B
Treatment Comparator Mean difference, ml (95 % CrI) Probability of non-inferiority
Margin (ml)
75 100 125
FF/VI 92/22 FP/SAL 250/50 −36 (−92–19) 92 % 99 % >99 %
FF/VI 92/22 BUD/FORM 320/9 −27 (−98–45) 91 % 98 % >99 %
FF/VI 184/22 FP/SAL 500/50 147 (48–247) >99 % >99 % >99 %
FF/VI 184/22 BUD/FORM 640/18 118 (−19–255) >99 % >99 % >99 %
C
Treatment Comparator Rate ratio (95 % CrI) Probability of non-inferiority
Margin (event rate ratio)
10 % 20 %
FF/VI 92/22 FP/SAL 250/50 1.164 (0.428–3.333) 74 % 78 %
FF/VI 92/22 BUD/FORM 320/9 0.985 (0.336–2.574) 82 % 86 %
D
Treatment Comparator Mean difference, units (95 % CrI) Probability of non-inferiority
Margin (units)
0.25 0.5
FF/VI 92/22 FP/SAL 250/50 0.060 (−0.104–0.224) >99 % >99 %
FF/VI 92/22 BUD/FORM 320/9 0.203 (−0.461–0.867) 90 % 96 %
For studies requiring patients to be treated with ICS or ICS/LABA at baseline; full covariate model
*Other relevant ICS/LABA: FP/SAL 250/50 mcg and 500/50 mcg; BUD/FORM 320/9 mcg and 640/18 mcg
a) change from baseline in morning PEF. b) change from baseline in FEV1. c) annual rate of moderate/severe exacerbations
†. d) AQLQ Total score
†Only study length was included as a covariate in analysis of moderate/severe exacerbations data
Note: All stated doses are mcg
AQLQ Asthma quality of life questionnaire, BUD Budesonide, CrI Credible interval, FORM Formoterol, FEV1 Forced expiratory volume in 1 s, FF Fluticasone furoate,
FP Fluticasone propionate, PEF Peak expiratory flow, SAL Salmeterol, VI Vilanterol
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mcg on exacerbations; however, the CrI for this estimate is
wide. Thus, the sensitivity analysis demonstrates that the
results for the exacerbations network are susceptible to the
studies that are included in the network. The findings of a
separate sensitivity analysis in which the exacerbations
analysis was rerun with alternate person-years definitions
were similar to those of the primary analysis.
Assessment of alternative modelling approaches
(Additional file 1: e-table 6)
The findings and details of the post-hoc analysis utilising
alternative modelling approaches–specifically, a frequen-
tist analysis using a random effects model with fixed study
and treatment effects, and a pairwise contrast analysis
(FEV1 endpoint only)–are reported in Additional file 1:e-table 6. The results of these analyses showed that,
where the application of the varied methodologies to
the dataset was feasible, PEF, FEV1 and AQLQ results
using these methodologies were consistent with those
of the primary MTC analyses.
Discussion
FF/VI represents the first once-daily ICS/LABA combin-
ation to be approved for use in the treatment of asthma;
two strengths of FF/VI have been approved in Europe
and Japan. We sought to compare the clinical efficacy of
FF/VI 92/22 mcg with that of twice-daily FP/SAL 250/50
mcg and BUD/FORM 320/9 mcg, and that of FF/VI
184/22 mcg with FP/SAL 500/50 mcg and BUD/FORM
640/18 mcg. FF/VI 92/22 mcg has previously been
shown to be comparable in efficacy in improving lung
Table 3 Posterior probability of non-inferiority for FF/VI versus other relevant ICS/LABA combination therapies*
A





FF/VI 92/22 FP/SAL 250/50 −0.046 (−0.102–0.010) 84 % 97 % >99 %
FF/VI 92/22 BUD/FORM 320/9 −0.037 (−0.106–0.032) 86 % 96 % 99 %
FF/VI 184/22 FP/SAL 500/50 0.163 (0.058–0.269) >99 % >99 % >99 %
FF/VI 184/22 BUD/FORM 640/18 0.099 (−0.043–0.241) 99 % >99 % >99 %
B





FF/VI 92/22 FP/SAL 250/50 93 (−43–230) >99 % >99 %
FF/VI 92/22 BUD/FORM 320/9 89 (−502–680) 93 % 95 %
For studies requiring patients to be treated with ICS only at baseline
*Other relevant ICS/LABA: FP/SAL 250/50 mcg and 500/50 mcg; BUD/FORM 320/9 mcg and 640/18 mcg
a) change from baseline in FEV1. b) AQLQ Total score
#
Note: All stated doses are mcg
# For reasons of model stability, only study length was included as a covariate in analysis of moderate/severe exacerbations data
AQLQ Asthma quality of life questionnaire, BUD Budesonide, CrI Credible interval, FORM Formoterol, FEV1 Forced expiratory volume in 1 s, FF Fluticasone furoate,
FP Fluticasone propionate, SAL Salmeterol, VI Vilanterol
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head-to-head randomised controlled trial [7].
Using an MTC approach, we examined the probability of
non-inferiority of once-daily FF/VI compared with corre-
sponding strengths of twice-daily FP/SAL and BUD/FORM
by combining data on clinical efficacy outcomes from sev-
eral RCTs. All three ICS/LABA combination therapies have
previously been shown to be associated with improvements
in these outcomes relative to placebo.
We chose to use a Bayesian, hierarchical MTC modelling
approach to synthesise evidence from RCTs conducted in
adolescents and adults with asthma that involved at least
one ICS/LABA comparator. Broad-scope searches were
used to identify as many studies as possible that were
potentially suitable for inclusion in the MTC. Exclusion
criteria were subsequently applied on an outcome-by-
outcome basis. The Bayesian approach that we used
enabled a probabilistic estimate of non-inferiority to be
generated directly from the posterior distribution [22].
To output meaningful probabilities of non-inferiority, it
was necessary to select suitable margins. The non-
inferiority margins used for the PEF analysis in this study,
12 l/min and 15 l/min, are well-established margins used
in numerous previous studies and based upon European
Medicines Agency guidelines [11, 23, 24]. For FEV1, the
margins of 75 ml, 100 ml and 125 ml were chosen based
upon the minimal clinically important difference (MCID)
of 230 ml [13] and non-inferiority margins used in previ-
ous comparative studies involving FF/VI [6] or FF [25].
For exacerbations, the non-inferiority margins of 10 % and
20 % rate ratio reductions are consistent with the marginof 1.18 used in a previous non-inferiority study of FP/SAL
vs FP [12]. The accepted MCID for the AQLQ is 0.5 [14],
hence the use of a margin of 0.25, representing half of the
MCID, preserves 50 % of the active comparator effect. We
consider that, as these margins are smaller than the MCID
and therefore imply higher thresholds for demonstrating
non-inferiority between treatments, they represent conser-
vative margins for the non-inferiority analysis. However, it
is important to note that a finding of a low probability of
non-inferiority, using such conservative margins, does not
imply lack of comparability or inferiority.
Based on these conservative margins, the results of the
primary MTC analyses suggest that there is a high prob-
ability that FF/VI 92/22 mcg is non-inferior to FP/SAL
250/50 mcg and BUD/FORM 320/9 mcg on lung function
(PEF and FEV1) and health status (AQLQ) endpoints, sup-
porting the findings of the previous head-to-head RCT of
FF/VI 92/22 mcg compared with FP/SAL 250/50 mcg. The
analysis of exacerbation rate was inconclusive owing to the
lack of sufficient data and disconnectedness of the network.
The effectiveness of any meta-analytic method can be
limited by the amount of clinical trial data available for
each of the treatments in the analysis. As a consequence of
the limited number of RCTs available to inform compari-
sons of ICS/LABA therapies in asthma, the CrI for most of
the non-inferiority estimates in our study were wide. More-
over, we decided a priori to treat different strengths of the
same therapies as different treatments. This represents
both a strength–in that the comparisons we have studied
are more precise–and a weakness of our approach, as com-
bining dosages may have produced a stronger and more
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outcomes. The CrI were particularly wide for the outcomes
of secondary interest (i.e. exacerbations and AQLQ). Exac-
erbations, in particular, are relatively rare events and are
therefore typically only examined in longer-term studies. In
addition, the primary endpoints of most RCTs in asthma
assess lung function, rather than exacerbations. As such,
our study network was weak with respect to exacerbations;
this MTC incorporated only six studies, including just one
study of FF/VI 92/22 mcg [5] and no studies of FF/VI 184/
22 mcg for the primary exacerbations analysis. The small
number of studies led to limited information in the net-
work and subsequent disconnections in treatment net-
works. The full model did not converge because of the
weak network. One consequence of this was that we were
unable to account for covariates in the exacerbations MTC
as was possible for the other three MTC outcomes. The
post-hoc assessment of alternative modelling approaches
showed that the findings of the lung function and health
status MTCs were consistent upon the application of
varied methodologies, including a frequentist approach, to
the data where the network was sufficiently connected to
permit this.
Population and endpoint heterogeneity in the studies in-
cluded in the MTC analyses was addressed as far as pos-
sible by our inclusion criteria to ensure that patient
populations were suitable for comparison. To minimise
study-to-study variability, studies were only included in
the primary PEF analysis if they reported mean change
from baseline averaged across the whole trial, rather than
from baseline to a specific timepoint. For the same reason,
studies were excluded from the exacerbations analysis if
the definition of exacerbation differed considerably from
that set out in the ATS/ERS Task Force recommendation
[8]. The findings of sensitivity analyses of both of these
outcomes, conducted using data from enlarged networks
derived from relaxed inclusion criteria, suggest that the
MTC findings are highly susceptible to the addition of
studies to the network.
Despite the measures we took in order to reduce
study-to-study variability as far as possible given the
nature of the analysis, over-dispersion was observed in
the primary analysis model distributions. Through
study-level covariate modelling within the MTC, we
assessed whether variables including study duration,
average patient age and exacerbation history affected
the comparisons; we sought to correct for this through
the incorporation of heterogeneity factors at the study
level. Significant covariate effects of baseline FEV1 and
study duration were observed in the PEF analysis only.
The observation that greater baseline FEV1 is associ-
ated with slightly greater improvement from baseline in
PEF is consistent with incompleteness of reversibility in
patients with more severe airflow limitation [26].Still, a limitation of this approach that should be borne
in mind in the interpretation of the results is that it is not
possible to correct for all confounding factors, particularly
as patient-level data were not available. For instance, al-
though the study inclusion criteria specified that patients
had to be uncontrolled/symptomatic at baseline, it was
not possible to ensure a consistent definition of “uncon-
trolled” across studies as the required data was often not
reported. Furthermore, the fact that we have synthesised
evidence from trials conducted at different periods of time
and in different regions means that there will inevitably be
some degree of underlying variation that could have influ-
enced the findings. For instance, basic standards of care
vary across regions and typically improve over time.
Although MTC are established as a useful tool for the
synthesis of evidence that is suitable for use in clinical
decision-making [27], to our knowledge, this is the first
study to apply this methodology to data from clinical trials
in asthma to investigate the relative efficacy of specific
treatments. In a recently-published network meta-analysis
in which data on treatment interventions in asthma were
combined across classes [28] and their effectiveness
assessed, ICS/LABA combination therapies were found to
be the most effective intervention for the prevention of
asthma exacerbations. In COPD, findings of meta-analyses
of treatment efficacy data [29, 30] have indicated that ICS/
LABA combination therapy have a greater positive effect
on COPD outcomes than alternative treatment modalities.
Conclusions
The findings of the MTC suggest that the efficacy of both
strengths of once-daily FF/VI in asthma is broadly compar-
able to that of corresponding doses of established twice-
daily ICS/LABA combinations, FP/SAL and BUD/FORM,
on lung function and health status outcomes of interest in
the primary study populations. The MTC supported the
findings of a previously-reported head-to-head randomised
controlled trial of FF/VI 92/22 mcg vs FP/SAL 250/50 mcg
in which it was shown that the efficacy of these treatments
in improving lung function and health status endpoints is
similar [7]. It should be borne in mind that the MTC find-
ings are obtained through the analysis of outcomes from
RCTs and any potential efficacy benefits that may derive
from treatment attributes such as once- vs twice-daily dos-
ing in real-world clinical practice will not be reflected in
these data.
Supplementary data update
The mixed treatment comparison was updated with
more recently published data; studies published between
18th December 2012 and 30th July 2014 were identified
by an update of the systematic review. Seven additional
studies were identified for inclusion in this update, thus
a total of 38 studies were included and are presented in
Svedsater et al. Asthma Research and Practice  (2016) 2:4 Page 11 of 12the study supplement (Additional file 2: Tables S1-S3).
The results including these data are in line with those of
the original analyses, and thus did not affect any of the
conclusions previously drawn.Additional files
Additional file 1: e-table 1: Characteristics of the studies and
treatment arms included in the MTC. e-table 2: Results of mixed
treatment comparisons for ICS/LABA treatments of interest (full covariate
model, if available). e-table 3: Summary of findings of covariate analysis, by
outcome of interest (primary analysis population; full covariate model, if
available). e-table 4: Results of mixed treatment comparisons by ICS/LABA
treatment. e-table 5: Posterior probability of non-inferiority for FF/VI versus
other relevant ICS/LABA combination therapies*, sensitivity analysis.
e-table 6: Outcomes of assessment of alternative modelling approaches.
Supplementary figure 1: Networks of study treatments, by outcome of
interest (sensitivity analysis population). (PDF 705 kb)
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